RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can do daily activities pretty well: ECOG 0–1
- Your tumor (or blood) has a PIK3CA mutation confirmed by the study’s local testing
- You must provide old tumor tissue or be willing to do a new tumor biopsy before starting treatment
- Your cancer must be advanced (unresectable or metastatic) and no longer responding to standard treatment, or you can’t tolerate it
- Depending on the study group: your tumors must be the right cancer type and measurable/evaluable on scans
- You must not have uncontrolled diabetes and should not have certain lung, heart rhythm, brain, or allergy problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
This trial tests a combination of three targeted therapies (inavolisib, ribociclib, and fulvestrant) in people with a specific type of advanced breast cancer that has a PIK3CA genetic change. The goal is to see if this new combination can shrink tumors or slow cancer growth, potentially offering a new option before other treatments are needed.
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
This trial tests a new drug, JYP0035, combined with fulvestrant for people with a specific type of advanced breast cancer that has a PIK3CA mutation. The goal is to see if this combination can help control the cancer better than standard treatments.
Hear when a new PIK3CA Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.